Combination adjuvants: The next generation of adjuvants?

Expert Review of Vaccines

Volumn 10, Issue 1, 2011, Pages 95-107

  Mutwiri, George ^a,b   Gerdts, Volker ^a   Van Drunen Littel Van Den Hurk, Sylvia ^a,b   Auray, Gael ^a   Eng, Nelson ^a   Garlapati, Srinivas ^a   Babiuk, Lorne A ^c   Potter, Andrew ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

adjuvants; delivery systems; immunostimulators; vaccines

Indexed keywords

AG85B ESAT 6 PROTEIN; ALUMINUM POTASSIUM SULFATE; AS 04; BCG VACCINE; CATHELIN RELATED ANTIMICROBIAL PEPTIDE; CHITOSAN; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; EMULSIGEN; HEPATITIS B SURFACE ANTIGEN; HOST DEFENSE PEPTIDE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IC 37; IMMUNOLOGICAL ADJUVANT; INDOLICIDIN; INFLUENZA VACCINE; KLKL5KLK PROTEIN; LIPOSOME; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; MIFAMURTIDE; MURAMYL DIPEPTIDE; MYCOBACTERIUM ANTIGEN; OVALBUMIN; PHOSPHORYL LIPID A; POLY[DI(SODIUM CARBOXYLATOETHYLPHENOXY)PHOSPHAZENE]; POLY[DI(SODIUM CARBOXYLATOPHENOXY)PHOSPHAZENE]; POLYINOSINIC POLYCYTIDYLIC ACID; POLYPHOSPHAZENE; QS 21; QUIL A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENTIATION; EMULSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOSTIMULATION; INJECTION SITE REACTION; MONOCYTE; NEUTROPHIL; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL; TUBERCULOSIS; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; BIOPHARMACEUTICS; DRUG COMBINATIONS; HUMANS; VACCINES;

EID: 78650430146     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.154     Document Type: Review

References (124)

1. Huang DB, Wu JJ, Tyring SK. A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. J. Infect. 49(3), 179-209 (2004).
2. Brunner S, Herndler-Brandstetter D, Weinberger B, Grubeck-Loebenstein B. Persistent viral infections and immune aging. Ageing Res. Rev. DOI: 10.1016/j. arr.2010.08.003 (2010) (Epub ahead of print).
3. Mosca F, Tritto E, Muzzi A et al. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl Acad. Sci. USA 105(30), 10501-10506 (2008).
4. Ramon G. Ann. Inst. Pasteur 38, 1 (1924).
5. Singh M, O'Hagan DT. Recent advances in veterinary vaccine adjuvants. Int. J. Parasitol. 33(5-6), 469-478 (2003).
6. Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24(33-34), 5937-5949 (2006).
7. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B. Vaccine adjuvants: current challenges and future approaches. J. Pharm. Sci. 98(4), 1278-1316 (2009).
8. Kool M, Soullie T, Van Nimwegen M et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating infammatory dendritic cells. J. Exp. Med. 205(4), 869-882 (2008).
9. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 infammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198), 1122-1126 (2008).
10. Franchi L, Nunez G. The Nlrp3 infammasome is critical for aluminium hydroxide-mediated IL-1p secretion but dispensable for adjuvant activity. Eur. J. Immunol. 38(8), 2085-2089 (2008).
11. Li H, Willingham SB, Ting JP, Re F. Cutting edge: infammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J. Immunol. 181(1), 17-21 (2008).
12. Marrack P, McKee AS, Munks MW Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9(4), 287-293 (2009).
13. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 26(26), 3209-3222 (2008).
14. Leroux-Roels I, Leroux-Roels G. Current status and progress of prepandemic and pandemic infuenza vaccine development. Expert Rev. Vaccines 8(4), 401-423 (2009).
15. Seubert A, Monaci E, Pizza M, O'Hagan DT, Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 180(8), 5402-5412 (2008).
16. Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 22(15-16), 1903-1913 (2004).
17. Owais M, Gupta CM. Liposome-mediated cytosolic delivery of macromolecules and its possible use in vaccine development. Eur. J. Biochem. 267(13), 3946-3956 (2000).
18. Stewart VA, McGrath SM, Walsh DS et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 24(42-43), 6483-6492 (2006).
19. Joseph A, Itskovitz-Cooper N, Samira S et al. A new intranasal infuenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS) I. Immunogenicity and effcacy studies in mice. Vaccine 24(18), 3990-4006 (2006).
20. Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin. Cancer Res. 13(15 Pt 2), S4652-S4654 (2007).
21. Lovgren K, Morein B. The requirement of lipids for the formation of immunostimulating complexes (iscoms). Biotechnol. Appl. Biochem. 10(2), 161-172 (1988).
22. Davis ID, Chen W, Jackson H et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proc. Natl Acad. Sci. USA 101(29), 10697-10702 (2004).
23. Smith RE, Donachie AM, Grdic D, Lycke N, Mowat AM. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. J. Immunol. 162(9), 5536-5546 (1999).
24. Jiang W, Swiggard WJ, Heufer C et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375(6527), 151-155 (1995).
25. Van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol. 27(1), 49-55 (2006).
26. Querec T, Bennouna S, Alkan S et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203(2), 413-424 (2006).
27. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 162(4), 2291-2298 (1999).
28. Miyagi K, Kawakami K, Kinjo Y et al. CpG oligodeoxynucleotides promote the host protective response against infection with Cryptococcus neoformans through induction of interferon-g production by CD4+ T cells. Clin. Exp. Immunol. 140(2), 220-229 (2005).
29. Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115(3), 739-746 (2005).
30. Heckelsmiller K, Beck S, Rall K et al. Combined dendritic cell-and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur. J. Immunol. 32(11), 3235-3245 (2002).
31. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. 5(6), 471-484 (2006).
32. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 61(3), 195-204 (2009).
33. Lemesre JL, Holzmuller P, Cavaleyra M, Goncalves RB, Hottin G, Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purifed excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 23(22), 2825-2840 (2005).
34. Cheng E, Cardenas-Freytag L, Clements JD. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine 18(1-2), 38-49 (1999).
35. Xu-Amano J, Jackson RJ, Fujihashi K, Kiyono H, Staats HF, McGhee JR. Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin. Vaccine 12(10), 903-911 (1994).
36. Katz JM, Lu X, Young SA, Galphin JC. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated infuenza virus vaccine. J. Infect. Dis. 175(2), 352-363 (1997).
37. Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine 25(19), 3752-3762 (2007).
38. Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect. Immun. 71(8), 4780-4788 (2003).
39. Didierlaurent AM, Morel S, Lockman L et al. AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183(10), 6186-6197 (2009).
40. Bagchi A, Herrup EA, Warren HS et al. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J. Immunol. 178(2), 1164-1171 (2007).
41. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6(8), 769-776 (2005).
42. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S et al. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 52(8), 2313-2322 (2005).
43. Sato S, Nomura F, Kawai T et al. Synergy and cross-tolerance between toll-like receptor (TLR) 2-and TLR4-mediated signaling pathways. J. Immunol. 165(12), 7096-7101 (2000).
44. Grossmann C, Tenbusch M, Nchinda G et al. Enhancement of the priming effcacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic Toll-like receptor ligands. BMC Immunol. 10, 43 (2009).
45. Zhu Q, Egelston C, Gagnon S et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J. Clin. Invest. 120(2), 607-616 (2010).
46. Mutwiri G, Van Drunen Littel-Van den Hurk S, Babiuk LA. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides. Adv. Drug Deliv. Rev. 61(3), 226-232 (2009).
47. Griebel PJ, Brownlie R, Manuja A et al. Bovine Toll-like receptor 9: a comparative analysis of molecular structure, function and expression. Vet. Immunol. Immunopathol. 108(1-2), 11-16 (2005).
48. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23, 275-306 (2005).
49. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374(6522), 546-549 (1995).
50. Yi AK, Peckham DW, Ashman RF, Krieg AM. CpG DNA rescues B cells from apoptosis by activating NFKB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. Int. Immunol. 11(12), 2015-2024 (1999).
51. Davis HL, Weeratna R, Waldschmidt TJ et al. CpG DNA is a potent enhancer of specifc immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160(2), 870-876 (1998).
52. Sparwasser T, Vabulas RM, Villmow B, Lipford GB, Wagner H. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur. J. Immunol. 30(12), 3591-3597 (2000). (Pubitemid 32005232)
53. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186(10), 1623-1631 (1997).
54. Ioannou XP, Griebel P, Hecker R, Babiuk LA, Van Drunen L., Van den Hurk S. The immunogenicity and protective effcacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J. Virol. 76(18), 9002-9010 (2002).
55. Oumouna M, Mapletoft J, Karvonen B, Babiuk LA, Van Drunen L, Van den Hurk S. Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine. J. Virol. 79, 2024-2032 (2005).
56. Roman M, Martin-Orozco E, Goodman JS et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3(8), 849-854 (1997).
57. Weeratna RD, McCluskie MJ, Xu Y, Davis HL. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 18(17), 1755-1762 (2000).
58. Krieg AM, Davis HL. Enhancing vaccines with immune stimulatory CpG DNA. Curr. Opin. Mol. Ther. 3(1), 15-24 (2001).
59. Ioannou XP, Gomis SM, Karvonen B, Hecker R, Babiuk LA, Van Drunen L, Van den Hurk S. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine 21(1-2), 127-137 (2002).
60. Ioannou XP, Griebel P, Mena A et al. Safety of CpG oligodeoxynucleotides in veterinary species. Antisense Nucleic Acid Drug Dev. 13(3), 157-167 (2003).
61. Rankin R, Pontarollo R, Gomis S et al. CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D. Vaccine 20(23-24), 3014-3022 (2002).
62. Davis HL, Suparto, II, Weeratna RR et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18(18), 1920-1924 (2000).
63. Cooper CL, Davis HL, Morris ML et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuVant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J. Clin. Immunol. 24(6), 693-701 (2004).
64. Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ. A Phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21(19-20), 2461-2467 (2003).
65. Cooper CL, Davis HL, Morris ML et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix infuenza vaccine. Vaccine 22(23-24), 3136-3143 (2004).
66. Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. 113(6), 1144-1151 (2004).
67. Kuball J, de Boer K, Wagner E et al. Pitfalls of vaccinations with WT1-, Proteinase3-and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer Immunol. Immunother. DOI: 10.1007/s00262-010-0929-7 (2010) (Epub ahead of print).
68. Ganz T. Defensins and host defense. Science 286(5439), 420-421 (1999).
69. Gallo RL, Murakami M, Ohtake T, Zaiou M. Biology and clinical relevance of naturally occurring antimicrobial peptides. J. Allergy Clin. Immunol. 110(6), 823-831 (2002).
70. Kurosaka K, Chen Q, Yarovinsky F, Oppenheim JJ, Yang D. Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptorlike 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J. Immunol. 174(10), 6257-6265 (2005).
71. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 17(4), 359-365 (2005).
72. De Y, Chen Q, Schmidt AP et al. LL-37, the neutrophil granule-and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192(7), 1069-1074 (2000).
73. Niyonsaba F, Iwabuchi K, Someya A et al. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 106(1), 20-26 (2002).
74. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J. Immunol. 169(7), 3883-3891 (2002).
75. Hsu CH, Chen C, Jou ML et al. Structural and DNA-binding studies on the bovine antimicrobial peptide, indolicidin: evidence for multiple conformations involved in binding to membranes and DNA. Nucleic Acids Res. 33(13), 4053-4064 (2005).
76. Selsted ME, Novotny MJ, Morris WL, Tang YQ, Smith W, Cullor JS. Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils. J. Biol. Chem. 267(7), 4292-4295 (1992).
77. Fritz JH, Brunner S, Birnstiel ML et al. The artifcial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens. Vaccine 22(25-26), 3274-3284 (2004).
78. Schellack C, Prinz K, Egyed A et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24(26), 5461-5472 (2006).
79. Agger EM, Rosenkrands I, Olsen AW et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 24(26), 5452-5460 (2006).
80. Riedl K, Riedl R, von Gabain A, Nagy E, Lingnau K. The novel adjuvant IC31 strongly improves infuenza vaccine-specifc cellular and humoral immune responses in young adult and aged mice. Vaccine 26(27-28), 3461-3468 (2008).
81. Kamath AT, Rochat AF, Valenti MP et al. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. PloS One 3(11), e3683 (2008).
82. Olafsdottir TA, Lingnau K, Nagy E, Jonsdottir I. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice. Scand. J. Immunol. 69(3), 194-202 (2009).
83. Bowdish DM, Davidson DJ, Scott MG, Hancock RE. Immunomodulatory activities of small host defense peptides. Antimicrob. Agents Chemother. 49(5), 1727-1732 (2005).
84. Kovacs-Nolan J, Mapletoft JW, Latimer L, Babiuk LA, Hurk SD. CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle. Vaccine 27(14), 2048-2054 (2009).
85. Kovacs-Nolan J, Mapletoft JW, Lawman Z, Babiuk LA, Van Drunen L, Van den Hurk S. Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice. J. Gen. Virol. 90(Pt 8), 1892-1905 (2009).
86. Kovacs-Nolan J, Latimer L, Landi A et al. The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody-and cell-mediated immune responses in mice. Vaccine 27(14), 2055-2064 (2009).
87. Hilpert K, Elliott MR, Volkmer-Engert R et al. Sequence requirements and an optimization strategy for short antimicrobial peptides. Chem. Biol. 13(10), 1101-1107 (2006).
88. Kindrachuk J, Jenssen H, Elliott M et al. A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine 27(34), 4662-4671 (2009).
89. McNeal MM, Rae MN, Ward RL. Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine 17(11-12), 1573-1580 (1999).
90. Payne LG, Jenkins SA, Woods AL et al. Poly[di(carboxylatophenoxy) phosphazene] (PCPP) is a potent immunoadjuvant for an infuenza vaccine. Vaccine 16(1), 92-98 (1998).
91. Wu JY, Wade WF, Taylor RK. Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice. Infect. Immun. 69(12), 7695-7702 (2001).
92. Mutwiri G, Benjamin P, Soita H, Babiuk LA. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with hepatitis B virus surface antigen. Vaccine 26(22), 2680-2688 (2008).
93. Mutwiri G, Benjamin P, Soita H et al. Poly[di(sodium carboxylatoethylphenoxy) phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with infuenza virus antigens. Vaccine 25(7), 1204-1213 (2007).
94. Mapletoft JW, Oumouna M, Kovacs-Nolan J et al. Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J. Gen. Virol. 89(Pt 1), 250-260 (2008).
95. Jiang W, Baker HJ, Smith BF. Mucosal immunization with helicobacter, CpG DNA, and cholera toxin is protective. Infect. Immun. 71(1), 40-46 (2003).
96. Cheng C, Bettahi I, Cruz-Fisher MI et al. Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin. Vaccine 27(44), 6239-6246 (2009).
97. Albu DI, Jones-Trower A, Woron AM, Stellrecht K, Broder CC, Metzger DW. Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodefciency virus type 1 glycoproteins. J. Virol. 77(10), 5589-5597 (2003).
98. Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366(9502), 2012-2018 (2005).
99. Alonso PL, Sacarlal J, Aponte JJ et al. Effcacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364(9443), 1411-1420 (2004).
100. Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuVant systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6(5), 723-739 (2007).
101. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv. Exp. Med. Biol. 667, 111-123 (2010).
102. Inohara N, Ogura Y, Fontalba A et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. 278(8), 5509-5512 (2003).
103. Ellouz F, Adam A, Ciorbaru R, Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 59(4), 1317-1325 (1974).
104. Moschos SA, Bramwell V W, Somavarapu S, Alpar HO. Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A. Vaccine 24(8), 1081-1086 (2006).
105. Moschos SA, Bramwell VW, Somavarapu S, Alpar HO. Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation. Vaccine 23(16), 1923-1930 (2005).
106. Jain V, Vyas SP, Kohli DV. Well-defned and potent liposomal hepatitis B vaccines adjuvanted with lipophilic MDP derivatives. Nanomedicine 5(3), 334-344 (2009).
107. Lindenstrom T, Agger EM, Korsholm KS et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 182(12), 8047-8055 (2009).
108. Chianese-Bullock KA, Pressley J, Garbee C et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte- macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J. Immunol. 174(5), 3080-3086 (2005).
109. Toubaji A, Hill S, Terabe M et al. The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine 25(31), 5882-5891 (2007).
110. Song S, Liu C, Wang J et al. Vaccination with combination of Fit3L and RANTES in a DNA prime-protein boost regimen elicits strong cell-mediated immunity and antitumor effect. Vaccine 27(7), 1111-1118 (2009).
111. Sharp FA, Ruane D, Claass B et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 infammasome. Proc. Natl Acad. Sci. USA 106(3), 870-875 (2009).
112. Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 59(9), 2978-2986 (1991).
113. O'Hagan DT, Jeffery H, Davis SS. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 11(9), 965-969 (1993).
114. O'Hagan DT, Jeffery H, Roberts MJ, McGee JP, Davis SS. Controlled release microparticles for vaccine development. Vaccine 9(10), 768-771 (1991).
115. O'Hagan DT, Rahman D, McGee JP et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 73(2), 239-242 (1991).
116. Diwan M, Tafaghodi M, Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J. Control Release 85(1-3), 247-262 (2002).
117. O'Hagan DT, Singh M, Kazzaz J et al. Synergistic adjuvant activity of eimmunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 20(27-28), 3389-3398 (2002).
118. Cleland JL, Barron L, Daugherty A et al. Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120. J. Pharm. Sci. 85(12), 1350-1357 (1997).
119. Tabata Y, Ikada Y. Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres. J. Pharm. Pharmacol. 39(9), 698-704 (1987).
120. Andrianov AK, Chen J, Payne LG. Preparation of hydrogel microspheres by coacervation of aqueous polyphosphazene solutions. Biomaterials 19(1-3), 109-115 (1998).
121. Andrianov AK, Marin A, Chen J. Synthesis, properties, and biological activity of poly[di(sodium carboxylatoethylphenoxy)phosphazene]. Biomacromolecules 7(1), 394-399 (2006).
122. Eng NF, Garlapati S, Gerdts V, Potter A, Babiuk LA, Mutwiri GK. The potential of polyphosphazenes for delivery of vaccine antigens and immunotherapeutic agents. Curr. Drug Deliv. 7(1), 13-20 (2010).
123. Wack A, Baudner BC, Hilbert AK et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to infuenza vaccine in mice. Vaccine 26(4), 552-561 (2008).
124. Mitchell LA, Joseph A, Kedar E, Barenholz Y, Galun E. Mucosal immunization against hepatitis A: antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid. Vaccine 24(25), 5300-5310 (2006).